DCTH vs. GLUE
DCTH (Delcath Systems, Inc.) and GLUE (Monte Rosa Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — DCTH in Medical Devices, GLUE in Biotechnology. Over the past 5 years, DCTH returned 3.68%/yr vs -7.59%/yr for GLUE. Their 0.22 correlation means their historical movements had little consistent relationship.
Performance
DCTH vs. GLUE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, DCTH achieves a 20.99% return, which is significantly higher than GLUE's 5.36% return.
DCTH
- 1D
- 1.50%
- 1M
- -7.42%
- 6M
- 23.31%
- YTD
- 20.99%
- 1Y
- 15.39%
- 3Y*
- 42.76%
- 5Y*
- 3.68%
- 10Y*
- —
- ALL TIME*
- -46.75%
GLUE
- 1D
- -27.16%
- 1M
- -31.76%
- 6M
- -19.49%
- YTD
- 5.36%
- 1Y
- 244.89%
- 3Y*
- 33.78%
- 5Y*
- -7.59%
- 10Y*
- —
- ALL TIME*
- -5.46%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $4.25M | $4.46M | $5.78M | |
| $33.43M | $32.05M | $26.85M |
DCTH vs. GLUE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
DCTH Delcath Systems, Inc. | 20.99% | -16.11% | 189.42% | 15.56% | -53.55% | -25.91% |
GLUE Monte Rosa Therapeutics, Inc. | 5.36% | 125.94% | 22.83% | -25.76% | -62.73% | -7.18% |
Correlation
The correlation between DCTH and GLUE is 0.19, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.19 |
Correlation (3Y) Balances recent behavior with more history. | 0.22 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.21 |
Correlation (All Time) Calculated using the full available price history since Jun 24, 2021 | 0.22 |
Fundamentals
DCTH:
$421.85M
GLUE:
$1.40B
DCTH:
$0.01
GLUE:
-$2.64
DCTH:
7.00
GLUE:
18.97
DCTH:
$65.45M
GLUE:
$42.95M
DCTH:
$77.75M
GLUE:
$34.56M
DCTH:
$222.00K
GLUE:
-$139.25M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DCTH vs. GLUE — Risk / Return Rank
DCTH
GLUE
DCTH vs. GLUE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Delcath Systems, Inc. (DCTH) and Monte Rosa Therapeutics, Inc. (GLUE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DCTH | GLUE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.15 | ||
| Sortino ratioReturn per unit of downside risk | -2.66 | ||
| Omega ratioGain probability vs. loss probability | 1.09 | 1.44 | -0.35 |
| Calmar ratioReturn relative to maximum drawdown | 0.41 | 5.62 | -5.22 |
| Martin ratioReturn relative to average drawdown | 0.83 | 12.36 | -11.53 |
Loading charts...
Drawdowns
DCTH vs. GLUE - Drawdown Comparison
The maximum DCTH drawdown since its inception was -99.96%, which is greater than GLUE's maximum drawdown of -94.08%. Use the drawdown chart below to compare losses from any high point for DCTH and GLUE.
Loading charts...
Drawdown Indicators
| DCTH | GLUE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.96% | -94.08% | -5.88% |
Max Drawdown (1Y)Largest decline over 1 year | -33.74% | -41.84% | +8.10% |
Max Drawdown (3Y)Largest decline over 3 years | -60.87% | -64.29% | +3.42% |
Max Drawdown (5Y)Largest decline over 5 years | -80.80% | -94.08% | +13.28% |
Current DrawdownCurrent decline from peak | -99.80% | -60.86% | -38.94% |
Average DrawdownAverage peak-to-trough decline | -96.47% | -73.78% | -22.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.48% | 19.05% | -2.57% |
Volatility
DCTH vs. GLUE - Volatility Comparison
The current volatility for Delcath Systems, Inc. (DCTH) is 10.23%, while Monte Rosa Therapeutics, Inc. (GLUE) has a volatility of 35.38%. This indicates that DCTH experiences smaller price fluctuations and is considered to be less risky than GLUE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DCTH | GLUE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.23% | 35.38% | -25.15% |
Volatility (6M)Calculated over the trailing 6-month period | 33.52% | 49.79% | -16.27% |
Volatility (1Y)Calculated over the trailing 1-year period | 48.02% | 97.54% | -49.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 72.50% | 101.44% | -28.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 109.21% | 100.99% | +8.22% |
Dividends
DCTH vs. GLUE - Dividend Comparison
Neither DCTH nor GLUE has paid dividends to shareholders.
Financials
DCTH vs. GLUE - Financials Comparison
This section allows you to compare key financial metrics between Delcath Systems, Inc. and Monte Rosa Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
DCTH and GLUE have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GLUE has higher volatility (35.38%) compared to DCTH (10.23%). In terms of maximum drawdown, DCTH dropped -99.96% vs GLUE's -94.08%.
GLUE currently has the higher Sharpe Ratio (2.43 vs 0.29), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for DCTH and GLUE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer